^
Association details:
| Biomarker: | TP53 wild-type + LRP1B wild-type |
|---|---|
| Cancer: | Lung Cancer |
| Drug Class: | PD-L1 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
TP53 and LRP1B Co-Wild Predicts Improved Survival for Patients with LUSC Receiving Anti-PD-L1 Immunotherapy
Published date:
07/12/2022
Excerpt:
...TP53/LRP1B co-wild LUSC conferred an elevated response rate in anti-PD-L1 therapy and improved survival, which was associated with a chromosome-stable phenotype and an activated immune microenvironment.
DOI:
https://doi.org/10.3390/cancers14143382
